Occurrence of a FAB-M1 AML in a child during treatment of APL: emergence of an immature clone or a therapy related-AML?
Lo Nigro
Luca
L
Center of Pediatric Hematology Oncology, University of Catania, via S.Sofia 78, 95123 Catania, Italy. lucaln@yahoo.com
Schiliro
Gino
G
D018906:Antineoplastic Agents, Alkylating / Q000008:administration & dosage / Q000009:adverse effects; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage; D002648:Child; D017809:Fatal Outcome; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000209:etiology* / Q000473:pathology; D015473:Leukemia, Promyelocytic, Acute / Q000188:drug therapy*; D008297:Male; D016609:Neoplasms, Second Primary / Q000209:etiology* / Q000473:pathology
D018906:Antineoplastic Agents, Alkylating